Tools

LEADER 03120cam a2200517 i 4500

001 ssj0001904058;

003 WaSeSS;

005 20251212090320.0;

006 m d ;

007 cr n ;

008 170927s2018 sz a sb 001 0 eng d;

010 a| 2017046401;

020 a| 9783318061000 (hard cover : alk. paper);

020 z| 9783318061017 (electronic version);

035 a| (WaSeSS)ssj0001904058;

040 a| DNLM/DLCc| DLCd| DLCd| WaSeSS;

042 a| pcc;

049 a| EREEa| NEHH;

050 00 a| RL110b| .A32 2018;

060 10 a| W1b| CU804L v.53 2018;

060 10 a| WR 650;

082 00 a| 616.5/062| 23;

245 00 a| Adverse reactions to biologicsh| [electronic resource] /c| volume editors, Llu©Ưs Puig, Barcelona, Wayne Gulliver, St. John's, NL.;

260 a| Basel ;a| New York :b| Karger,c| 2018.;

300 a| x, 108 pages :b| color illustrations ;c| 26 cm.;

490 1 a| Current problems in dermatology,x| 1421-5721 ;v| vol. 53;

504 a| Includes bibliographical references and index.;

505 0 a| Adverse reactions to biologics in psoriasis / Lockwood, S.J., Prens, L.M.; Kimball, A.B. -- Clinical trial and registry data / Gooderham, M., Papp, K. -- Immunosuppression/infections across indications / Al-Khalili, A., Dutz, J.P. -- The immunogenicity of biologic therapies / Garcias, S., Demengeot, J. -- Paradoxical reaction S : anti-tumor necrosis factor alpha agents, Ustekinumab, Secukinumab, Ixekizumab, and others / Puig, L. -- Bullous diseases / Corbaux, C., Joly, P. -- Adverse reactions of antibody-therapy for primary cutaneous lymphomas : Rituximab, Brentuximab vedotin, Alemtuzumab, and Mogamulizumab / Saulite, I., Guenova, E., Hoetzenecker, W. -- Adverse reactions to biologics : melanoma (Ipilimumab, Nivolumab, Pembrolizumab) / Hwang, S.J.E., Fern©Łndez-Pe©łas, P. -- Skin manifestations of targeted antineoplastic therapy / Sanmart©Ưn, O.;

506 a| Available only to authorized users.;

538 a| Mode of access: World Wide Web;

650 12 a| Skin Diseasesx| drug therapy=| ^A921380;

650 22 a| Biological Productsx| adverse effects=| ^A923483;

650 22 a| Biological Productsx| therapeutic use=| ^A921434;

655 0 a| Electronic books.=| ^A491897;

700 1 a| Puig Sanz, Llu©Ưs.?| UNAUTHORIZED;

700 1 a| Gulliver, Wayne.=| ^A1377035;

830 0 a| Current problems in dermatology ;v| v. 53.x| 1421-5721=| ^A885079;

856 40 z| Full text available from Karger eBooks Collection 2017u| https://go.openathens.net/redirector/ecu.edu?url=https%3A%2F%2Fkarger.com%2Fbook%2Fdoi%2F10.1159%2Fisbn.978-3-318-06101-7;

949 a| CLICK ON WEB ADDRESSw| ASISh| JOYNER188;

949 a| CLICK ON WEB ADDRESSw| ASISh| HSL77;

949 a| CLICK ON WEB ADDRESSw| ASISh| JMUSIC60;

596 a| 1 3 4;

998 a| 4912394;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 4912394-1001l| JNETm| JOYNERr| Ys| Yt| JNESSBKu| 9/22/2018x| EBOOKz| JERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 4912394-2001l| HSLELECm| HSLr| Ys| Yt| HEBKu| 9/22/2018x| EBOOKz| HERESOURCE;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 4912394-3001l| MNETm| JMUSICr| Ys| Yt| MNESSBKu| 9/22/2018x| EBOOKz| JERESOURCE;

Other author	Puig Sanz, Llu©Ưs.
Other author	Gulliver, Wayne.
Format	Electronic
Publication Info	Basel ; New York : Karger, 2018.
Description	x, 108 pages : color illustrations ; 26 cm.
Supplemental Content	Full text available from Karger eBooks Collection 2017
Subjects	Skin Diseases--drug therapy. Biological Products--adverse effects. Biological Products--therapeutic use.

Series	Current problems in dermatology, 1421-5721 ; vol. 53 Current problems in dermatology ; v. 53. 1421-5721 ^A885079
Contents	Adverse reactions to biologics in psoriasis / Lockwood, S.J., Prens, L.M.; Kimball, A.B. -- Clinical trial and registry data / Gooderham, M., Papp, K. -- Immunosuppression/infections across indications / Al-Khalili, A., Dutz, J.P. -- The immunogenicity of biologic therapies / Garcias, S., Demengeot, J. -- Paradoxical reaction S : anti-tumor necrosis factor alpha agents, Ustekinumab, Secukinumab, Ixekizumab, and others / Puig, L. -- Bullous diseases / Corbaux, C., Joly, P. -- Adverse reactions of antibody-therapy for primary cutaneous lymphomas : Rituximab, Brentuximab vedotin, Alemtuzumab, and Mogamulizumab / Saulite, I., Guenova, E., Hoetzenecker, W. -- Adverse reactions to biologics : melanoma (Ipilimumab, Nivolumab, Pembrolizumab) / Hwang, S.J.E., Fern©Łndez-Pe©łas, P. -- Skin manifestations of targeted antineoplastic therapy / Sanmart©Ưn, O.
Bibliography note	Includes bibliographical references and index.
Access restriction	Available only to authorized users.
Technical details	Mode of access: World Wide Web
Genre/form	Electronic books.
LCCN	2017046401
ISBN	9783318061000 (hard cover : alk. paper)

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Adverse reactions to biologics / volume editors, Llu©Ưs Puig, Barcelona, Wayne Gulliver, St. John's, NL.

Click here for more information about this title

Availability